TN2013000372A1 - Bis(fluoroalkyl)-1,4-benzodiazepinone compounds - Google Patents
Bis(fluoroalkyl)-1,4-benzodiazepinone compoundsInfo
- Publication number
- TN2013000372A1 TN2013000372A1 TNP2013000372A TN2013000372A TN2013000372A1 TN 2013000372 A1 TN2013000372 A1 TN 2013000372A1 TN P2013000372 A TNP2013000372 A TN P2013000372A TN 2013000372 A TN2013000372 A TN 2013000372A TN 2013000372 A1 TN2013000372 A1 TN 2013000372A1
- Authority
- TN
- Tunisia
- Prior art keywords
- compounds
- fluoroalkyl
- bis
- benzodiazepinone compounds
- ch2ch2cf3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161466238P | 2011-03-22 | 2011-03-22 | |
| PCT/US2012/030021 WO2012129353A1 (fr) | 2011-03-22 | 2012-03-22 | Composés bis(fluoroalkyl)-1,4-benzodiazépinone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2013000372A1 true TN2013000372A1 (en) | 2015-01-20 |
Family
ID=45894701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2013000372A TN2013000372A1 (en) | 2011-03-22 | 2013-09-19 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US8629136B2 (fr) |
| EP (1) | EP2688873B1 (fr) |
| JP (1) | JP5873923B2 (fr) |
| KR (1) | KR101948347B1 (fr) |
| CN (1) | CN103717576B (fr) |
| AR (1) | AR085471A1 (fr) |
| AU (1) | AU2012230904B2 (fr) |
| BR (1) | BR112013024059B1 (fr) |
| CA (1) | CA2830902C (fr) |
| CL (1) | CL2013002690A1 (fr) |
| CO (1) | CO6771446A2 (fr) |
| CY (1) | CY1116423T1 (fr) |
| DK (1) | DK2688873T3 (fr) |
| EA (1) | EA022530B1 (fr) |
| ES (1) | ES2534080T3 (fr) |
| HK (1) | HK1189218A1 (fr) |
| HR (1) | HRP20150273T1 (fr) |
| IL (1) | IL228534A (fr) |
| MA (1) | MA35036B1 (fr) |
| MX (1) | MX2013010420A (fr) |
| MY (1) | MY161233A (fr) |
| PE (1) | PE20140626A1 (fr) |
| PL (1) | PL2688873T3 (fr) |
| PT (1) | PT2688873E (fr) |
| RS (1) | RS53843B1 (fr) |
| SG (1) | SG193555A1 (fr) |
| SI (1) | SI2688873T1 (fr) |
| SM (1) | SMT201500091B (fr) |
| TN (1) | TN2013000372A1 (fr) |
| TW (1) | TWI530489B (fr) |
| UY (1) | UY33961A (fr) |
| WO (1) | WO2012129353A1 (fr) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3072526T3 (pl) | 2009-10-16 | 2019-04-30 | Oncomed Pharm Inc | Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem DLL4 i środków antyhipertensyjnych |
| LT3485903T (lt) | 2011-09-23 | 2023-02-27 | Mereo Biopharma 5, Inc. | Vegf/ dll4 surišantys agentai ir jų panaudojimas |
| EP2897960B1 (fr) | 2012-09-21 | 2016-08-03 | Bristol-Myers Squibb Company | Composés hétérocycliques tricycliques utilisables en tant qu'inhibiteurs du récepteur notch |
| TWI614238B (zh) * | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥 |
| CN104822677A (zh) * | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | 氟烷基-1,4-苯并二氮杂*酮化合物 |
| WO2014047374A1 (fr) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Composés alkyl, fluoroalkyl-1,4-benzodiazépinones |
| EP2897941B1 (fr) * | 2012-09-21 | 2016-09-07 | Bristol-Myers Squibb Company | Promédicaments de composés 1,4-benzodiazépinones |
| CN104854097A (zh) * | 2012-09-21 | 2015-08-19 | 百时美施贵宝公司 | N-取代的二(氟烷基)-1,4-苯并二氮杂*酮化合物 |
| EP2897944B1 (fr) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Composés de 1,5-benzodiazépinone substituée |
| CN104822665A (zh) * | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | 用作Notch抑制剂的氟烷基和氟环烷基1,4-苯并二氮杂*酮化合物 |
| JP2015529250A (ja) * | 2012-09-21 | 2015-10-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | フルオロアルキルジベンゾジアゼピノン化合物 |
| US9599620B2 (en) | 2012-10-31 | 2017-03-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| EP2981267A1 (fr) * | 2013-04-04 | 2016-02-10 | Bristol-Myers Squibb Company | Traitement combiné pour le traitement de maladies prolifératives |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| CN103435562B (zh) * | 2013-08-26 | 2016-02-24 | 华东理工大学 | 6-取代苯并二氮卓-2,4-二酮类化合物及其用途 |
| US10174015B2 (en) | 2014-10-31 | 2019-01-08 | Xiamen University | Substituted heterocyclic derivative, preparation method and use thereof |
| AU2015338974B2 (en) * | 2014-10-31 | 2021-08-26 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| CN104352488B (zh) * | 2014-10-31 | 2016-08-31 | 厦门大学 | 一类取代杂环衍生物在制备治疗疼痛药物中的应用 |
| CN104356082B (zh) * | 2014-10-31 | 2016-07-13 | 厦门大学 | 一类取代杂环衍生物及其制备方法 |
| CN104892532B (zh) * | 2015-05-20 | 2017-09-08 | 成都理工大学 | 手性3‑取代1,3,4,5‑四氢‑1,4‑苯二氮*‑2‑酮的合成工艺 |
| JP7112324B2 (ja) | 2015-07-22 | 2022-08-03 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｒｓｖ阻害剤としてのベンゾジアゼピン誘導体 |
| EP3353204B1 (fr) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Anticorps anti-vegf/dll4 bi-spécifique pour le traitement du cancer de l'ovaire résistant au platine |
| CN108699077B (zh) | 2016-01-15 | 2021-03-02 | 英安塔制药有限公司 | 作为rsv抑制剂的杂环化合物 |
| EA201892075A1 (ru) | 2016-03-15 | 2019-04-30 | Оризон Дженомикс, С.А. | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей |
| JP7076459B2 (ja) | 2017-02-16 | 2022-05-27 | エナンタ ファーマシューティカルズ インコーポレイテッド | ベンゾジアゼピン誘導体の製造プロセス |
| WO2018201051A1 (fr) | 2017-04-28 | 2018-11-01 | Novartis Ag | Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase |
| WO2018201056A1 (fr) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase |
| US10752598B2 (en) | 2017-06-07 | 2020-08-25 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as RSV inhibitors |
| WO2019006295A1 (fr) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | Composés hétérocycliques utilisés en tant qu'inhibiteurs du vrs |
| WO2019006291A1 (fr) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | Composés hétérocycliques utilisés en tant qu'inhibiteurs du vrs |
| EP3438128B1 (fr) * | 2017-08-04 | 2020-05-20 | Alzheimur 2012 S.L. | Anticorps anti preseniline pour une utilisation dans la prévention et/ou le traitement du cancer |
| WO2019067864A1 (fr) | 2017-09-29 | 2019-04-04 | Enanta Pharmaceuticals, Inc. | Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv |
| WO2019094903A1 (fr) * | 2017-11-13 | 2019-05-16 | Enanta Pharmaceuticals, Inc. | Procédé pour la résolution de dérivés benzodiazépin-2-one et benzoazépin-2-one |
| WO2019094920A1 (fr) | 2017-11-13 | 2019-05-16 | Enanta Pharmaceuticals, Inc. | Dérivés d'azépin-2-one en tant qu'inhibiteurs du vrs |
| US10975094B2 (en) | 2018-04-11 | 2021-04-13 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| SG11202011041YA (en) | 2018-05-06 | 2020-12-30 | Ayala Pharmaceuticals Inc | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof |
| US20210379079A1 (en) | 2018-05-06 | 2021-12-09 | Ayala Pharmaceuticals Inc. | Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
| US20210220372A1 (en) * | 2018-05-15 | 2021-07-22 | Bristol-Myers Squibb Company | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
| AU2019271044A1 (en) * | 2018-05-15 | 2021-01-14 | Ayala Pharmaceuticals Inc. | Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma |
| BR112020023975A2 (pt) | 2018-05-24 | 2021-02-23 | Ayala Pharmaceuticals Inc. | composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas |
| AU2019277029C1 (en) | 2018-06-01 | 2024-01-04 | Novartis Ag | Binding molecules against BCMA and uses thereof |
| CN113710276B (zh) | 2019-03-18 | 2024-03-29 | 英安塔制药有限公司 | 苯二氮䓬衍生物作为rsv抑制剂 |
| US11179400B2 (en) | 2019-04-09 | 2021-11-23 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| EP3969001A4 (fr) * | 2019-05-15 | 2023-02-22 | Ayala Pharmaceuticals Inc. | Composés de bisfluoroalkyl-1,4-benzodiazépinone pour le traitement du cancer du sein activé par notch |
| JP2022538237A (ja) | 2019-06-24 | 2022-09-01 | ノバルティス アーゲー | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| KR20220101083A (ko) | 2019-10-04 | 2022-07-19 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스 헤테로사이클릭 화합물 |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| WO2022010882A1 (fr) | 2020-07-07 | 2022-01-13 | Enanta Pharmaceuticals, Inc, | Dérivés de dihydroquinoxaline et de dihydropyridopyrazine utilisés comme inhibiteurs de rsv |
| EP4208162A1 (fr) | 2020-09-03 | 2023-07-12 | Bristol-Myers Squibb Company | Polymorphes de composés de bis(fluoroalkyl)-1,4-benzodiazépinone et leurs utilisations |
| WO2022086840A1 (fr) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Composés hétérocycliques en tant qu'agents antiviraux |
| WO2022122667A1 (fr) | 2020-12-07 | 2022-06-16 | Cellestia Biotech Ag | Combinaisons pharmaceutiques pour le traitement du cancer |
| EP4008324A1 (fr) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinaisons comprenant un inhibiteur d'une protéine anti-apoptotique, telle que bcl-2, bcl-xl, bclw ou mcl-1, et un inhibiteur de voie de signalisation notch pour le traitement du cancer |
| IL305189A (en) | 2021-02-26 | 2023-10-01 | Enanta Pharm Inc | Heterocyclic antiviral compounds |
| CN117794536A (zh) | 2021-06-02 | 2024-03-29 | 塞莱斯蒂亚生物技术股份公司 | 在治疗自身免疫性和炎症性疾病的方法中使用的化合物 |
| WO2023079132A1 (fr) | 2021-11-08 | 2023-05-11 | Cellestia Biotech Ag | Combinaisons pharmaceutiques pour le traitement du cancer |
| EP4223292A1 (fr) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Combinaisons pharmaceutiques pour le traitement du cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5324726A (en) | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
| US5852010A (en) | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CA2250203A1 (fr) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibiteurs de transferase de farnesyl-proteine |
| US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
| NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
| US6737038B1 (en) | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| DE69926254D1 (de) | 1998-11-12 | 2005-08-25 | Bristol Myers Squibb Pharma Co | Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden |
| BR9917082A (pt) | 1998-12-24 | 2001-11-06 | Du Pont Pharm Co | Compostos inibidores da produção de proteìnas a"beta", método de tratamento de disfunções neurológicas associadas com a produção de "beta"-amilóide, composição farmacêutica e, método de inibição da atividade de y-secretase |
| EP2062583B1 (fr) | 1999-04-30 | 2012-12-26 | The Regents of the University of Michigan | Applications thérapeutiques de benzodiazépines pro-apoptotiques |
| US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
| US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
| EP1222176A1 (fr) | 1999-10-08 | 2002-07-17 | Bristol-Myers Squibb Pharma Company | AMINO SULFONAMIDES DE LACTAME UTILISES COMME INHIBITEURS DE LA PRODUCTION DE PROTEINE A$g(b) |
| WO2001051919A2 (fr) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | Formation, identification et analyse a productivites elevees de formes solides diverses |
| JP2003520266A (ja) | 2000-01-24 | 2003-07-02 | メルク シャープ エンド ドーム リミテッド | γ−セクレターゼ阻害薬 |
| US6525044B2 (en) | 2000-02-17 | 2003-02-25 | Bristol-Myers Squibb Company | Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production |
| US6495540B2 (en) | 2000-03-28 | 2002-12-17 | Bristol - Myers Squibb Pharma Company | Lactams as inhibitors of A-β protein production |
| JP2003529594A (ja) | 2000-03-31 | 2003-10-07 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | Ａβタンパク質産生の阻害剤としてのサクシノイルアミノ複素環 |
| IL151576A0 (en) | 2000-04-03 | 2003-04-10 | Bristol Myers Squibb Pharma Co | Cyclic lactams as inhibitors of a-beta protein production |
| AU2001253108A1 (en) | 2000-04-03 | 2001-10-15 | Bristol-Myers Squibb Pharma Company | Cyclic lactams as inhibitors of a-beta protein production |
| GB0008710D0 (en) | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic compounds |
| US6632812B2 (en) | 2000-04-11 | 2003-10-14 | Dupont Pharmaceuticals Company | Substituted lactams as inhibitors of Aβ protein production |
| US6878363B2 (en) | 2000-05-17 | 2005-04-12 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| GB0012671D0 (en) | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
| CA2379445C (fr) | 2000-06-01 | 2007-08-21 | Bristol-Myers Squibb Pharma Company | Lactames substitues par des succinates cycliques en tant qu'inhibiteurs de la production de la proteine .beta. |
| US7001901B2 (en) | 2002-08-27 | 2006-02-21 | Bristol-Myers Squibb Company | Tetrazolylpropionamides as inhibitors of Aβ protein production |
| JP4719466B2 (ja) | 2002-09-20 | 2011-07-06 | アロー セラピューティクス リミテッド | ベンゾジアゼピン誘導体およびそれらを含有する医薬組成物 |
| PL378405A1 (pl) | 2003-02-04 | 2006-04-03 | F. Hoffmann-La Roche Ag | Pochodne malonoamidu jako inhibitory <$Egamma> - sekretazy |
| GB0312365D0 (en) | 2003-05-30 | 2003-07-02 | Univ Aston | Novel 3-substituted-1, 4-benzodiazepines |
| KR100838852B1 (ko) | 2003-09-09 | 2008-06-16 | 에프. 호프만-라 로슈 아게 | 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체 |
| EP1795198A1 (fr) | 2005-12-09 | 2007-06-13 | Hubrecht Laboratorium | Traitement de l'esophage de Barret |
| EP1996182A4 (fr) | 2006-02-27 | 2009-08-12 | Univ Johns Hopkins | Traitement anticancéreux utilisant des inhibiteurs de gamma-sécrétases |
| CA2645756C (fr) | 2006-03-27 | 2013-12-31 | F. Hoffmann-La Roche Ag | Derives de malonamide en tant qu'inhibiteurs de la gamma secretase |
| EP2069317A2 (fr) | 2006-09-20 | 2009-06-17 | F. Hoffmann-Roche AG | Dérivés 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazépine |
| KR101136260B1 (ko) | 2007-08-14 | 2012-04-19 | 일라이 릴리 앤드 캄파니 | 감마-세크레타제 억제제로서의 아제핀 유도체 |
| MA33076B1 (fr) | 2008-01-11 | 2012-03-01 | Hoffmann La Roche | Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer |
| US8637493B2 (en) | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
| US20120225860A1 (en) | 2011-03-02 | 2012-09-06 | John Frederick Boylan | Method for administration of a gamma secretase inhibitor |
-
2012
- 2012-02-24 TW TW101106426A patent/TWI530489B/zh active
- 2012-03-21 AR ARP120100932A patent/AR085471A1/es not_active Application Discontinuation
- 2012-03-21 UY UY0001033961A patent/UY33961A/es active IP Right Grant
- 2012-03-22 MA MA36323A patent/MA35036B1/fr unknown
- 2012-03-22 JP JP2014501220A patent/JP5873923B2/ja active Active
- 2012-03-22 MY MYPI2013003410A patent/MY161233A/en unknown
- 2012-03-22 SI SI201230162T patent/SI2688873T1/sl unknown
- 2012-03-22 SG SG2013070743A patent/SG193555A1/en unknown
- 2012-03-22 PE PE2013002083A patent/PE20140626A1/es active IP Right Grant
- 2012-03-22 PT PT127111029T patent/PT2688873E/pt unknown
- 2012-03-22 MX MX2013010420A patent/MX2013010420A/es active IP Right Grant
- 2012-03-22 ES ES12711102.9T patent/ES2534080T3/es active Active
- 2012-03-22 DK DK12711102T patent/DK2688873T3/en active
- 2012-03-22 AU AU2012230904A patent/AU2012230904B2/en active Active
- 2012-03-22 PL PL12711102T patent/PL2688873T3/pl unknown
- 2012-03-22 KR KR1020137027347A patent/KR101948347B1/ko active IP Right Grant
- 2012-03-22 US US13/426,730 patent/US8629136B2/en active Active
- 2012-03-22 RS RS20150150A patent/RS53843B1/en unknown
- 2012-03-22 EP EP12711102.9A patent/EP2688873B1/fr active Active
- 2012-03-22 BR BR112013024059-8A patent/BR112013024059B1/pt active IP Right Grant
- 2012-03-22 CA CA2830902A patent/CA2830902C/fr active Active
- 2012-03-22 WO PCT/US2012/030021 patent/WO2012129353A1/fr active Application Filing
- 2012-03-22 CN CN201280025022.2A patent/CN103717576B/zh active Active
- 2012-03-22 EA EA201391324A patent/EA022530B1/ru not_active IP Right Cessation
-
2013
- 2013-09-17 CL CL2013002690A patent/CL2013002690A1/es unknown
- 2013-09-17 IL IL228534A patent/IL228534A/en active IP Right Grant
- 2013-09-19 TN TNP2013000372A patent/TN2013000372A1/fr unknown
- 2013-09-20 CO CO13224494A patent/CO6771446A2/es unknown
- 2013-12-09 US US14/100,896 patent/US8822454B2/en active Active
-
2014
- 2014-01-30 HK HK14101033.1A patent/HK1189218A1/xx unknown
-
2015
- 2015-03-10 HR HRP20150273TT patent/HRP20150273T1/hr unknown
- 2015-04-13 SM SM201500091T patent/SMT201500091B/xx unknown
- 2015-04-17 CY CY20151100355T patent/CY1116423T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2013000372A1 (en) | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds | |
| TN2015000102A1 (en) | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors | |
| PH12016501204A1 (en) | Syk inhibitors | |
| CY1121357T1 (el) | Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις | |
| NZ715747A (en) | Syk inhibitors | |
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| BR112014005226A2 (pt) | derivados de benzonitrila como inibidores de cinase | |
| UY31545A1 (es) | Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones | |
| PH12015500063B1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
| IN2015DN01119A (fr) | ||
| MX2015008187A (es) | Inhibidores de alk deuterados. | |
| NZ707773A (en) | Methods of treating liver diseases | |
| MX2014003455A (es) | Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide. | |
| NZ624040A (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| NZ622953A (en) | Novel soft rock inhibitors |